We are live on ! Find out more
ARCT icon

Arcturus Therapeutics

28 hedge funds and large institutions have $56.1M invested in Arcturus Therapeutics in 2015 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

577% more capital invested

Capital invested by funds: $8.29M → $56.1M (+$47.8M)

0% more funds holding

Funds holding: 2828 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

46% less call options, than puts

Call options by funds: $552K | Put options by funds: $1.01M

Holders
28
Holders Change
Holders Change %
0%
% of All Funds
0.74%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
10
Increased
7
Reduced
7
Closed
10
Calls
$552K
Puts
$1.01M
Net Calls
-$463K
Net Calls Change
-$234K

ARCT Hedge Fund Activity: Q1 2015 in Review

28 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2015, worth a combined $56.1M — up 577% from $8.29M a quarter earlier.

Fund positioning in ARCT was balanced in Q1 2015: 10 funds opened new positions, 10 closed out, 7 added to existing stakes and 7 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $9.78M. The largest seller was Millennium Management, exiting entirely with an estimated $863K sold.

  • 28 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2015, unchanged from Q4 2014.
  • Funds reported $56.1M of Arcturus Therapeutics stock for Q1 2015, up 577% quarter-over-quarter.
  • 10 funds opened new Arcturus Therapeutics positions in Q1 2015 and 10 closed out, a net change of 0 holders.
  • The largest Arcturus Therapeutics buyer in Q1 2015 was Broadfin Capital, an estimated $9.78M added.
  • The largest Arcturus Therapeutics seller in Q1 2015 was Millennium Management, an estimated $863K sold.

Based on aggregated 13F filings for Q1 2015.